** Shares of gene sequencing equipment maker Illumina ILMN.O fall 4.7% to $117 premarket
** Co, late on Thursday, forecast 2025 revenue largely below Wall Street estimates
** Co expects 2025 revenue between $4.28 bln and $4.40 bln, below analysts' average estimate of $4.39 bln at midpoint, according to data compiled by LSEG
** China, which accounts for about 7% of Illumina's sales, placed co on its "unreliable entity" list earlier this week
** Illumina said its forecast does not reflect any impact from announcement from China
** "The lack of adjusting could mean there's hope they could be removed from the 'unreliable entity list' or that they can't yet quantify it" - Piper Sandler analysts
** Up to last close, stock down ~12% in the past 12 months
(Reporting by Mariam Sunny in Bengaluru)
((Mariam.ESunny@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。